Alector Announces Proposed Public Offering of Common Stock
16 Janvier 2024 - 10:01PM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced that it
intends to offer and sell, subject to market and other conditions,
shares of its common stock in an underwritten public offering. In
connection with the proposed offering, Alector expects to grant the
underwriter a 30-day option to purchase up to an additional 15% of
the total number of shares of its common stock offered in the
public offering. There can be no assurance as to whether or when
the proposed offering may be completed or as to the actual size or
terms of the proposed offering. All of the shares in the proposed
offering are being sold by Alector.
Cantor Fitzgerald & Co. is acting as sole
book-running manager for the proposed offering.
The proposed offering is being made pursuant to
a shelf registration statement on Form S-3 (File No. 333- 270126)
that was previously filed with and subsequently declared effective
by the Securities and Exchange Commission (“SEC”) on May 1, 2023.
The proposed offering will be made only by means of a prospectus,
including a prospectus supplement, forming a part of the effective
registration statement. The preliminary prospectus supplement and
accompanying prospectus relating to the proposed offering will be
filed with the SEC and will be available on the SEC’s website at
http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus relating to the proposed offering,
when available, may be obtained from: Cantor Fitzgerald &
Co., Attention: Capital Markets, 110 East
59th Street, 6th Floor, New York, NY 10022, or by
e-mail at prospectus@cantor.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About AlectorAlector is a
clinical-stage biotechnology company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a
root cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and seek to treat
indications, including Alzheimer’s disease and genetically defined
frontotemporal dementia patient populations. Alector is
headquartered in South San Francisco, California.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are
not limited to, statements regarding Alector’s expectations
regarding the completion, timing and size of the proposed offering
and Alector’s expectations with respect to granting the underwriter
a 30-day option to purchase additional shares. Such statements are
subject to numerous risks and uncertainties that may cause actual
events or results to differ materially from current expectations
and beliefs, including but not limited to risks and uncertainties
as set forth in Alector’s filings with the SEC, including the
Company’s Annual Reports on Form 10-K and Quarterly Reports on Form
10-Q, as well as the other documents Alector files from time to
time with the SEC. These documents contain and identify important
factors that could cause the actual results for Alector to differ
materially from those contained in Alector’s forward-looking
statements. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Alector specifically
disclaims any obligation to update any forward-looking statement,
except as required by law.
Alector Contacts:
AlectorKatie Hogan 202-549-0557katie.hogan@alector.com
1AB (media)Dan
Budwick973-271-6085 dan@1abmedia.com
Argot Partners (investors)Laura Perry
212.600.1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Alector (NASDAQ:ALEC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024